DoD Kidney Cancer, Postdoctoral and Clinical Fellowship Award | W81XWH 22 KCRP PCFA

Opportunity Information: Apply for W81XWH 22 KCRP PCFA

The DoD Kidney Cancer Research Program (KCRP) FY22 Postdoctoral and Clinical Fellowship Award is designed to help recent PhD and/or medical school graduates build the skills, publication record, and research independence needed to become future leaders in kidney cancer research. The core idea is to fund a focused period of mentored training during a postdoctoral and/or clinical fellowship where the fellow leads a kidney cancer project as the principal investigator (PI), while also following a structured career development plan. The program is looking for projects that are genuinely ambitious and positioned to make meaningful advances in kidney cancer research and/or patient care, rather than small, incremental next steps.

A central theme of the opportunity is impact. Reviewers are expecting a clear explanation of how the work could accelerate progress toward ending kidney cancer, whether that impact is nearer-term (for example, enabling a new diagnostic approach or clarifying a clinically relevant mechanism) or longer-term (such as laying the groundwork for future therapeutics or major shifts in disease understanding). Applications are also expected to identify the patients or at-risk populations who would ultimately benefit, so the project is not just scientifically interesting but also tied to real needs in kidney cancer.

The research strategy must be positioned for potential breakthroughs. The award can support high-risk/high-reward ideas that are still early, as well as projects supported by preliminary data that are closer to clinical translation. Regardless of stage, the application needs to show a strong rationale and well thought-out logic, and it should reflect rigorous study planning: appropriate controls, enough methodological detail to judge feasibility, a statistical plan, and a realistic discussion of pitfalls and alternative approaches. Human subjects research and the use of human anatomical substances are allowed, but clinical trials are explicitly not permitted under this announcement. The opportunity draws a clear line between allowable clinical research (such as patient-oriented studies, epidemiology, outcomes research, and certain technology development efforts) and disallowed clinical trials, defined as prospectively assigning human subjects to interventions to evaluate outcomes.

An important structural feature is that the fellow is the PI. The postdoc or clinical fellow is expected to take primary responsibility for writing key components like the project narrative and the researcher development plan, with guidance from the mentor. Prior kidney cancer experience is not strictly required for the PI, but both the proposed project and the career development plan must be kidney cancer-focused. Applications must also make a strong case that the fellow has the trajectory to become an independent kidney cancer investigator, using evidence such as qualifications, prior achievements and honors, first-author publications, previous funding if applicable, and strong letters of recommendation.

Mentorship is treated as a major factor in the likelihood of success. The mentor (or co-mentor) is expected to bring relevant expertise in kidney cancer research and/or patient care, with recent publications and active funding that demonstrate they can support the work. If the primary mentor does not have established kidney cancer expertise, the program requires formal co-mentorship from an experienced kidney cancer researcher. The application must describe not only the mentor's credentials, but also how the mentor will actively support both the research and the fellow's development. A limited track record of mentoring trainees can potentially be outweighed by an exceptionally strong and well-structured development plan, but the responsibility to prove that is on the applicant.

The researcher development plan is not a generic training statement; it is a required, individualized roadmap for becoming an independent kidney cancer researcher. Applicants need to explain why the research environment is well suited for their growth, what specific training and career-development activities will occur (for example, technical skills, conceptual training, clinical exposure where relevant, grant writing, publishing, networking, and mentorship structure), and how these elements fit together into a realistic path toward independence. Multidisciplinary approaches are encouraged, and if a project involves multiple disciplines or departments, the application should clearly show how those pieces integrate and how the fellow will gain meaningful experience across them.

From an administrative and funding standpoint, awards are issued as assistance agreements, meaning they will be made as either a grant or a cooperative agreement depending on how much involvement the DoD anticipates having during the project. If substantial involvement is expected (such as collaboration or participation by the funding agency), the mechanism may be a cooperative agreement; if not, it may be a standard grant. The anticipated direct costs for the full performance period are capped at $195,000. Program-level expectations were to fund about six awards, with an estimated total allocation of about $1.87 million, and awards were to be made no later than September 30, 2023, subject to federal fund availability and the outcome of scientific and programmatic review. Funds associated with FY22 awards were anticipated to remain available for use through September 30, 2028, reflecting the limited period in which those fiscal-year funds can be obligated and spent.

The announcement also highlights alignment with broader federal priorities, including recommendations from the congressionally mandated Metastatic Cancer Task Force, and encourages applicants to consider addressing those recommendations when appropriate and within the scope of the kidney cancer program priorities. Collaboration is another emphasized priority, particularly partnerships between military or Veteran institutions and non-military institutions, with the goal of leveraging unique populations, infrastructure, and expertise to produce research that matters for the Warfighter community as well as the general public.

Finally, the opportunity includes clear regulatory expectations for projects involving humans or animals. DoD-funded research involving human subjects, human anatomical substances, or cadavers must receive approval not only from a local IRB or ethics committee, but also from the USAMRDC Human Research Protection Office (HRPO) before research begins, and applicants are advised to plan for up to about three months for that additional review after submitting complete materials. For multi-institution human subjects research, a plan for single IRB arrangements is required, including identification of the lead institution responsible for master protocol and consent materials. For animal studies, local IACUC approval is not required at submission, but projects must undergo additional DoD-level review through ACURO, with applicants advised to plan for roughly three to four months for that process. The program also signals expectations around rigor and reproducibility in preclinical work, referencing established standards (including principles like randomization, blinding, and sample-size estimation) and recommending use of ARRIVE 2.0 reporting guidance.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Kidney Cancer, Postdoctoral and Clinical Fellowship Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 11, 2022.
• Applicants must submit their applications by Jul 14, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 6 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 KCRP PCFA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: